Publications - Sunanda V. Kane, M.D.

Back to research profile

  1. Singh S, Jiv Singh Nagpal S, Murad MH, Yadav S, Kane SV, Pardi DS, Talwalkar JA, Loftus EV Jr. Inflammatory Bowel Disease is Associated with an Increased Risk of Melanoma: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2013 May 02. [Epub ahead of print]
    View PubMed
  2. Kane S. "Doctor, I Just Can't": Nonadherence to Surveillance Colonoscopy. Inflamm Bowel Dis. 2013 Mar; 19(3):540-1.
    View PubMed
  3. Singh S, Kumar N, Loftus EV Jr, Kane SV. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):864-72.
    View PubMed
  4. Hodgkins P, Yen L, Yarlas A, Karlstadt R, Solomon D, Kane S. Impact of MMX(R) Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2013 Feb; 19(2):386-96.
    View PubMed
  5. Kane S, Leighton J, Kefalas C, Cohen L, Katz P, Rizk M, Pike I, Lashner B, Ho I, Pochapin M, Seabrook M, Greenwald D, Demarco D, Johnson D. Quality commitment: the newly established American College of Gastroenterology Quality Council to meet the needs of clinical gastroenterology. Am J Gastroenterol. 2013 Jan; 108(1):7-9.
    View PubMed
  6. Samuel S, Bruining DH, Loftus EV Jr, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):49-54.e1. Epub 2012 Aug 16.
    View PubMed
  7. Kane S. Establishing an inflammatory bowel disease practice in an accountable world. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1301-4.
    View PubMed
  8. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, Hanson KA, Tremaine WJ, Bruining DH, Faubion WA, Pardi DS, Harmsen WS, Zinsmeister AR, Loftus EV. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012 Dec; 18(12):2203-8. Epub 2012 Mar 14.
    View PubMed
  9. Horst SN, Kane S. Multi-Matrix System (MMX(R)) mesalamine for the treatment of mild-to-moderate ulcerative colitis. Expert Opin Pharmacother. 2012 Oct; 13(15):2225-32. Epub 2012 Sep 13.
    View PubMed
  10. Kane S. What physicians don't know about patient dietary beliefs and behavior can make a difference. Expert Rev Gastroenterol Hepatol. 2012 Sep; 6(5):545-7.
    View PubMed
  11. Bernick SJ, Kane S. Drug transfer to the fetus and to the breastfeeding infant: what do we know? Curr Drug Deliv. 2012 Jul; 9(4):350-5.
    View PubMed
  12. Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am. 2012 Jun; 41(2):483-95. Epub 2012 Feb 16.
    View PubMed
  13. Solomon D, Yarlas A, Hodgkins P, Karlstadt R, Yen L, Kane S. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. Aliment Pharmacol Ther. 2012 Jun; 35(12):1386-96. Epub 2012 Apr 27.
    View PubMed
  14. Kane S, Becker B, Harmsen S, Kurian A, Morisky D, Zinsmeister A. Response to trindade et Al. Am J Gastroenterol. 2012 Jun; 107(6):952.
    View PubMed
  15. Kane S, Katz S, Jamal MM, Safdi M, Dolin B, Solomon D, Palmen M, Barrett K. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2012 Jun; 18(6):1026-33. Epub 2011 Aug 11.
    View PubMed
  16. Kane S, Becker B, Harmsen WS, Kurian A, Morisky DE, Zinsmeister AR. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol. 2012 Feb; 107(2):154-60.
    View PubMed
  17. Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal behcet disease. Gastroenterol Hepatol (N Y). 2012 Feb; 8(2):103-12.
    View PubMed
  18. Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2011 Dec; 5(6):679-84.
    View PubMed
  19. Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis. 2011 Dec; 17(12):2585-93. Epub 2011 Apr 11.
    View PubMed
  20. Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Dec; 106(12):2070-7; quiz 2078. Epub 2011 Sep 06.
    View PubMed
  21. Kane SV, Sumner M, Solomon D, Jenkins M. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011 Dec; 56(12):3463-70. Epub 2011 Aug 31.
    View PubMed
  22. Feagins LA, Holubar SD, Kane SV, Spechler SJ. Current strategies in the management of intra-abdominal abscesses in Crohn's disease. Clin Gastroenterol Hepatol. 2011 Oct; 9(10):842-50. Epub 2011 May 05.
    View PubMed
  23. Kowalczyk R, Kane S. Inflammatory Bowel Disease: A Primary Care Primer. Consultant. 2011 Oct; 51(10):713-8.
  24. Kane SV. Preparing for biologic or immunosuppressant therapy. Gastroenterol Hepatol (N Y). 2011 Aug; 7(8):544-6.
    View PubMed
  25. Flynn A, Kane S. Mucosal healing in Crohn's disease and ulcerative colitis: what does it tell us? Curr Opin Gastroenterol. 2011 Jul; 27(4):342-5.
    View PubMed
  26. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol. 2011 Jun 14; 17(22):2696-701.
    View PubMed
  27. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2011 Jun; 40(2):399-413, ix. Epub 2011 Apr 06.
    View PubMed
  28. Thia KT, Loftus EV Jr, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn WJ. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011 Jun; 17(6):1257-64. Epub 2010 Sep 27.
    View PubMed
  29. Levesque BG, Kane SV. Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease. Gastroenterol Hepatol (N Y). 2011 May; 7(5):295-301.
    View PubMed
  30. Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):601-16. Epub 2011 Mar 15.
    View PubMed
  31. Ford AC, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):617-29. Epub 2011 Mar 15.
    View PubMed
  32. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P, American College of Gastroenterology IBD Task Force. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
    View PubMed
  33. Levesque BG, Kane SV. IBD: measuring what counts-safety of IBD medications in pregnancy. Nat Rev Gastroenterol Hepatol. 2011 Mar; 8(3):126-8. Epub 2011 Feb 08.
    View PubMed
  34. Holubar SD, Kane S. Prevention and treatment of postproctectomy infertility. Semin. Colon Rectal Surg. 2011; 22(4):249-54.
  35. Kane S. Preparing the patient for immunosuppressive therapy. Curr Gastroenterol Rep. 2010 Dec; 12(6):502-6.
    View PubMed
  36. Swoger JM, Loftus EV Jr, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn WJ. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010 Nov; 16(11):1912-21.
    View PubMed
  37. Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts. Aliment Pharmacol Ther. 2010 Nov; 32(9):1051-8. Epub 2010 Sep 03.
    View PubMed
  38. Bernick SJ, Kane S. Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients. Expert Rev Clin Immunol. 2010 Jul; 6(4):677-82.
    View PubMed
  39. Chang JY, Marks RS, Nagorney DM, Sanderson SO, Kane S. Ulcerative colitis, infliximab, and hepatic epithelioid hemangioendothelioma: who is to blame? Case Report. Therap Adv Gastroenterol. 2010 May; 3(3):203-6.
    View PubMed
  40. Travis AC, Katz PO, Kane SV. Mentoring in gastroenterology. Am J Gastroenterol. 2010 May; 105(5):970-2.
    View PubMed
  41. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May; 105(5):1133-9. Epub 2010 Feb 09.
    View PubMed
  42. Rubin DT, Dubinsky MC, Panaccione R, Siegel CA, Binion DG, Kane SV, Hopper J. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010 Apr; 55(4):1044-52. Epub 2009 Sep 04.
    View PubMed
  43. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3. Epub 2010 Jan 11.
    View PubMed
  44. Bernick SJ, Kane S. Improving adherence in inflammatory bowel disease. Pract Gastroenterol. 2010; 34(2):17-22.
  45. Kane S. Does treatment schedule matter? Once daily versus divided doses of 5-ASAs. Dig Dis. 2010; 28(3):478-82. Epub 2010 Sep 30.
    View PubMed
  46. Kane S. A 38-year-old with recurrent colitis. Is it noncompliance? Clin Gastroenterol Hepatol. 2009 Nov; 7(11):1164-7. Epub 2009 Jul 01.
    View PubMed
  47. Moscandrew M, Kane S. Inflammatory bowel diseases and management considerations: fertility and pregnancy. Curr Gastroenterol Rep. 2009 Oct; 11(5):395-9.
    View PubMed
  48. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009 Oct; 26(10):936-46. Epub 2009 Oct 16.
    View PubMed
  49. Afif W, Leighton JA, Hanauer SB, Loftus EV Jr, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View PubMed
  50. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009 Sep; 15(9):1399-409.
    View PubMed
  51. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol. 2009 Aug; 43(7):613-6.
    View PubMed
  52. Kane S, Lu F, Kornbluth A, Awais D, Higgins PD. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009 May; 15(5):796-800.
    View PubMed
  53. Kane SV, Accortt NA, Magowan S, Brixner D. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009 Apr 15; 29(8):855-62. Epub 2009 Jan 17.
    View PubMed
  54. Okoro NI, Kane SV. Gender-related issues in the female inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2009 Apr; 3(2):145-54.
    View PubMed
  55. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009 Jan; 104(1):228-33.
    View PubMed
  56. Kane S. Endoscopic healing should be a goal for everyone with ulcerative colitis. Inflamm Bowel Dis. 2008 Nov 04. [Epub ahead of print]
    View PubMed
  57. Kane S. What are the minimal requirements for a diagnosis of inflammatory bowel disease? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S148-9.
    View PubMed
  58. Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Sep 1; 28(5):598-605. Epub 2008 Jun 28.
    View PubMed
  59. Kane SV, Loftus EV Jr, Dubinsky MC, Sederman R. Disease perceptions among people with Crohn's disease. Inflamm Bowel Dis. 2008 Aug; 14(8):1097-101.
    View PubMed
  60. Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis. 2008 Aug; 14(8):1158-60.
    View PubMed
  61. Quin A, Kane S, Ulitsky O. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab. Nat Clin Pract Gastroenterol Hepatol. 2008 May; 5(5):278-81. Epub 2008 Mar 25.
    View PubMed
  62. Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008 May; 103(5):1193-6. Epub 2008 Jan 02.
    View PubMed
  63. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008 Apr; 53(4):1020-4. Epub 2007 Oct 13.
    View PubMed
  64. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008 Mar; 103(3):631-6. Epub 2007 Oct 17.
    View PubMed
  65. Shugart YY, Silverberg MS, Duerr RH, Taylor KD, Wang MH, Zarfas K, Schumm LP, Bromfield G, Steinhart AH, Griffiths AM, Kane SV, Barmada MM, Rotter JI, Mei L, Bernstein CN, Bayless TM, Langelier D, Cohen A, Bitton A, Rioux JD, Cho JH, Brant SR. An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29. Genes Immun. 2008 Mar; 9(2):161-7. Epub 2008 Jan 31.
    View PubMed
  66. Selby L, Kane S, Wilson J, Balla P, Riff B, Bingcang C, Hoellein A, Pande S, de Villiers WJ. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008 Feb; 14(2):253-8.
    View PubMed
  67. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008 Jan; 14(1 Suppl A):s2-12; quiz s13-5.
    View PubMed
  68. Kane SV. Patient Adherence in IBD. Primary Care Quartlerly. 2008; 12(1):39-44.
  69. Kane SV. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs. 2008; 68(18):2601-9.
    View PubMed
  70. Okoro N, Kane S. Abnormal cervical cytology and inflammatory bowel disease: Impact of immunosuppression. Pract Gastroenterol. 2008; 32(11):33-4, 36.
  71. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. Patient Prefer Adherence. 2008; 2:253-8. Epub 2008 Feb 02.
    View PubMed
  72. Kane SV. Overcoming adherence issues in ulcerative colitis. Gastroenterol Hepatol (N Y). 2007 Oct; 3(10):795-9.
    View PubMed
  73. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct; 133(4):1106-12. Epub 2007 Jul 25.
    View PubMed
  74. Dassopoulos T, Nguyen GC, Bitton A, Bromfield GP, Schumm LP, Wu Y, Elkadri A, Regueiro M, Siemanowski B, Torres EA, Gregory FJ, Kane SV, Harrell LE, Franchimont D, Achkar JP, Griffiths A, Brant SR, Rioux JD, Taylor KD, Duerr RH, Silverberg MS, Cho JH, Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Inflamm Bowel Dis. 2007 Aug; 13(8):975-83.
    View PubMed
  75. Silverberg MS, Duerr RH, Brant SR, Bromfield G, Datta LW, Jani N, Kane SV, Rotter JI, Philip Schumm L, Hillary Steinhart A, Taylor KD, Yang H, Cho JH, Rioux JD, Daly MJ, NIDDK IBD Genetics Consortium. Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease. Eur J Hum Genet. 2007 Mar; 15(3):328-35. Epub 2007 Jan 10.
    View PubMed
  76. Hanauer SB, Kane SV, Plevy SE, Siegel CA. A case-based discussion on managing Crohn's disease: Integrating the new generation of anti-TNF-alpha therapies. Gastroenterol. Hepatol. 2007; 3(12 SUPPL. 35):3-13.
  77. Kane SV. The complexity of compliance and persistence in ulcerative colitis. Gastroenterol. Hepatol. 2007; 3(9 Suppl 28):3-10.
  78. Parekh N, Kane S. The pregnant IBD patient: what every gastroenterologist should consider. Pract Gastroenterol. 2007; 31(2):17-28.
  79. Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2007; 1(1):89-100.
  80. Kane S. Urogenital complications of Crohn's disease. Am J Gastroenterol. 2006 Dec; 101(12 Suppl):S640-3.
    View PubMed
  81. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006 Oct 17; 145(8):557-63.
    View PubMed
  82. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther. 2006 Oct 1; 24(7):1099-103.
    View PubMed
  83. Kane S, Reddy D. Guidelines do help change behavior in the management of osteoporosis by gastroenterologists. Am J Gastroenterol. 2006 Aug; 101(8):1841-4. Epub 2006 Jun 30.
    View PubMed
  84. Reddy D, Siegel CA, Sands BE, Kane S. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2006 Jul; 101(7):1569-73.
    View PubMed
  85. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul; 131(1):283-311.
    View PubMed
  86. Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul; 131(1):278-82.
    View PubMed
  87. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM, Hanauer SB, Hanson J, Harris ML, Kane SV, Orkwis HK, Lahaie R, Oliva-Hemker M, Pare P, Wild GE, Rioux JD, Yang H, Duerr RH, Cho JH, Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006 May; 101(5):1012-23.
    View PubMed
  88. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Mar 1; 23(5):577-85.
    View PubMed
  89. Keswani RN, Sauk J, Kane SV. Factitious diarrhea masquerading as refractory celiac disease. South Med J. 2006 Mar; 99(3):293-5.
    View PubMed
  90. Kane SV. Asacol -- a review focusing on ulcerative colitis. US Gastroenterology Review. 2006 Mar:22-5.
  91. Blair SA, Kane SV, Clayburgh DR, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest. 2006 Feb; 86(2):191-201.
    View PubMed
  92. Kane S. Colon lesions: pathology specific to women. Gastrointest Endosc Clin N Am. 2006 Jan; 16(1):165-73.
    View PubMed
  93. Loftus EV, Kane SV, Lichtensetein GR, Sandborn WJ. Contemporary management of ulcerative colitis: the patient's perspective. Gastroenterology & Hepatology. 2006; 2(9):4-15.
  94. Lichtenstein GR, Kane SV, Velayos FS. Short and long term benefits of successful mucosal healing and patient compliance in ulcerative colitis. Gastroenterology & Hepatology. 2006; 2(12):S1-10.
  95. Kane SV. Another biologic for Crohn's disease: not so fast. Evid Based Gastroenterol. 2006; 7(2):5-6.
  96. Kane SV. Best of DDW 2006. Gastroenterology & Hepatology. 2006; 2(7):521-4.
  97. Giannini EG, Kane SV, Testa R, Savarino V. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'? Dig Liver Dis. 2005 Oct; 37(10):723-31.
    View PubMed
  98. Sauk J, Kane S. The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert Opin Pharmacother. 2005 Sep; 6(11):1833-9.
    View PubMed
  99. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8.
    View PubMed
  100. Kane S. Gender issues in the management of irritable bowel syndrome. Int J Fertil Womens Med. 2005 Mar-Apr; 50(2):79-82.
    View PubMed
  101. Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005 Jan; 100(1):102-5.
    View PubMed
  102. Kane SV, Flicker M, Katz-Nelson F. Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission. J Clin Gastroenterol. 2005 Jan; 39(1):32-5.
    View PubMed
  103. Kane SV. Controversies in IBD case management. Clinician. 2005; 23(1).
  104. Kane SV, DeVos M, Riley S, Frieri G, Mittman U. Compliance with IBD therapy: facts, concerns and ways forward. Rev Gastroenterol Disord. 2005; 5(2):101-5.
  105. Kane SV. Gender issues in inflammatory bowel diseases. Women's Health. 2005; 1(3):401-8.
  106. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
    View PubMed
  107. Kane S, Cohen SM, Hart J. Acute sinusoidal obstruction syndrome after 6-thioguanine therapy for Crohn's disease. Inflamm Bowel Dis. 2004 Sep; 10(5):652-4.
    View PubMed
  108. Kane S, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol. 2004 Aug; 99(8):1523-6.
    View PubMed
  109. Lichtenstein GR, Cuffari C, Kane SV, Hanauer S, Present DH. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21.
    View PubMed
  110. Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10.
    View PubMed
  111. Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord. 2004 Spring; 4(2):86-91.
    View PubMed
  112. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004 Jan 15; 19(2):179-89.
    View PubMed
  113. Kane SV. Adherence issues in the patient with inflammatory bowel disease. Pract Gastroenterol. 2004; 28(9):16-22.
  114. Kane SV. Managing the pregnant patient with inflammatory bowel disease. Pract Gastroenterol. 2004; 28(10):16-26.
  115. Kane SV. Breastfeeding and IBD: safety and management issues. Inflammatory Bowel Disease Monitor. 2004; 6(2):50-2.
  116. Kane SV, Borisov NN, Brixner D. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Manag Care. 2004; 10:S216-26.
  117. Kane SV. Another reason why immunomodulators are better than steroids: lack of asosciation with postoperative infections. Evid Based Gastroenterol. 2004; 5(1):26-7.
  118. Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003 Sep; 9(5):281-9.
    View PubMed
  119. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003 Fall; 3(4):210-8.
    View PubMed
  120. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14.
    View PubMed
  121. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003 May; 1(3):170-3.
    View PubMed
  122. Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2003 Mar; 32(1):323-40.
    View PubMed
  123. Tuvlin JA, Kane SV. Novel therapies in the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2003 Mar; 12(3):483-90.
    View PubMed
  124. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan; 114(1):39-43.
    View PubMed
  125. Kane SV. Some reassuring news for 6-MP users. Evid Based Gastroenterol. 2003; 4(3):100-1.
  126. Kane SV. Bugs as drugs: ready for the "mainstream"? Evid Based Gastroenterol. 2003; 4(4):135-6.
  127. Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol. 2002 Aug; 35(2):149-50.
    View PubMed
  128. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002 Aug; 16(8):1509-17.
    View PubMed
  129. Kane S. Gender issues in the management of inflammatory bowel disease and irritable bowel syndrome. Int J Fertil Womens Med. 2002 May-Jun; 47(3):136-42.
    View PubMed
  130. Kane SV. Managing pregnancy in IBD. Inflammatory Bowel Disease Monitor. 2002; 4(1):1-12.
  131. Kane SV. Yet another steroid that we will learn to avoid: beclometasone dipropionate for ulcerative colitis. Evid Based Gastroenterol. 2002; 3(1):92-4.
  132. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33.
    View PubMed
  133. Kane SV. Novel therapies in the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2001 Jul; 10(7):1223-9.
    View PubMed
  134. Kane S. Caring for women with inflammatory bowel disease. J Gend Specif Med. 2001; 4(1):54-9.
    View PubMed
  135. Kane SV. Non-steroidal anti-inflammatory drugs are associated with an increased risk of disease activity in inflammatory bowel disease. Evid Based Gastroenterol. 2001; 2(1):20-1.
  136. Kane SV. Growth hormone for Crohn's disease: not the new wonder drug. Evid Based Gastroenterol. 2001; 2(1):28-9.
  137. Kane SV. Is ursodiol protective against colorectal cancer in patients with ulcerative colitis and primary sclerosing cholangitis? Evid Based Gastroenterol. 2001; 2(2):70-1.
  138. Kane SV. A decreased murine content does not necessarily equate to improved efficacy in targeted biologics. Evid Based Gastroenterol. 2001; 2(3):115.
  139. Kane S, Brasitus T. Histoplasmosis capsulatum as a cause of lower gastrointestinal bleeding in common variable immunodeficiency. Dig Dis Sci. 2000 Nov; 45(11):2133-5.
    View PubMed
  140. Kane SV. Colorectal cancer surveillance of patients with ulcerative colitis is disorganized and inconsistent. Evid Based Gastroenterol. 2000; 1(1):20-1.
  141. Kane SV. Methotrexate appear efficacious and safe for maintenance in Crohn's disease. Evid Based Gastroenterol. 2000; 1(2):70-1.
  142. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
    View PubMed
  143. Kane S. Patient compliance and outcomes. Inflamm Bowel Dis. 1999 May; 5(2):134-7.
    View PubMed
  144. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998 Oct; 93(10):1867-72.
    View PubMed
  145. Kane SV, Ganger DR. Management of hepatocellular carcinoma: staging and treatment. Am J Ther. 1997 Jan; 4(1):39-45.
    View PubMed
  146. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology. 1990 Oct; 99(4):1032-6.
    View PubMed
  147. Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol. 1990 Sep; 85(9):1083-7.
    View PubMed
  148. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology. 1989 Dec; 97(6):1442-7.
    View PubMed
  149. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology. 1989 Aug; 97(2):255-9.
    View PubMed


Appointments | Contact Us | Give to Mayo Clinic | Search

LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE

Use of this site signifies your agreement to the terms of use.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.